- Home
- KOD vs TRML Comparison
KOD vs TRML Comparison
Compare KOD & TRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOD
- TRML
- Stock Information
- Founded
- KOD 2009
- TRML 2021
- Country
- KOD United States
- TRML United States
- Employees
- KOD N/A
- TRML N/A
- Industry
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- TRML Biotechnology: Pharmaceutical Preparations
- Sector
- KOD Health Care
- TRML Health Care
- Exchange
- KOD Nasdaq
- TRML Nasdaq
- Market Cap
- KOD 454.7M
- TRML 509.8M
- IPO Year
- KOD 2018
- TRML N/A
- Fundamental
- Price
- KOD $3.45
- TRML $17.04
- Analyst Decision
- KOD Hold
- TRML Strong Buy
- Analyst Count
- KOD 4
- TRML 8
- Target Price
- KOD $8.00
- TRML $52.86
- AVG Volume (30 Days)
- KOD 306.7K
- TRML 244.7K
- Earning Date
- KOD 03-27-2025
- TRML 03-13-2025
- Dividend Yield
- KOD N/A
- TRML N/A
- EPS Growth
- KOD N/A
- TRML N/A
- EPS
- KOD N/A
- TRML N/A
- Revenue
- KOD N/A
- TRML N/A
- Revenue This Year
- KOD N/A
- TRML N/A
- Revenue Next Year
- KOD N/A
- TRML $14.29
- P/E Ratio
- KOD N/A
- TRML N/A
- Revenue Growth
- KOD N/A
- TRML N/A
- 52 Week Low
- KOD $2.19
- TRML $11.87
- 52 Week High
- KOD $11.60
- TRML $46.36
- Technical
- Relative Strength Index (RSI)
- KOD 28.84
- TRML 67.49
- Support Level
- KOD $3.59
- TRML $13.85
- Resistance Level
- KOD $3.89
- TRML $15.66
- Average True Range (ATR)
- KOD 0.35
- TRML 0.97
- MACD
- KOD 0.07
- TRML 0.69
- Stochastic Oscillator
- KOD 4.98
- TRML 97.36
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.
About TRML Tourmaline Bio Inc.
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.